Join

Compare · NVS vs TPST

NVS vs TPST

Side-by-side comparison of Novartis AG (NVS) and Tempest Therapeutics Inc. (TPST): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVS and TPST operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $282.12B, about 9883.5x TPST ($28.5M).
  • Over the past year, NVS is up 32.9% and TPST is down 71.6% - NVS leads by 104.6 points.
  • TPST has been more active in the news (7 items in the past 4 weeks vs 1 for NVS).
  • NVS has more recent analyst coverage (25 ratings vs 7 for TPST).
PerformanceNVS+32.92%TPST-71.63%
2025-05-01+0.00%2026-04-30
MetricNVSTPST
Company
Novartis AG
Tempest Therapeutics Inc.
Price
$147.99+3.48%
$2.02+16.76%
Market cap
$282.12B
$28.5M
1M return
-3.10%
+24.69%
1Y return
+32.92%
-71.63%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
1
7
Recent ratings
25
7
NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

TPST

Tempest Therapeutics Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.

Latest NVS

Latest TPST